Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "CAS"

1563 News Found

Norms for fixing prices of medicines
Policy | December 20, 2023

Norms for fixing prices of medicines

NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201


NHA organizes a multi-stakeholder meet for ABDM microsites
News | December 20, 2023

NHA organizes a multi-stakeholder meet for ABDM microsites

ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring


Clariant Healthcare debuts in CPhI India
News | December 20, 2023

Clariant Healthcare debuts in CPhI India

Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India


Venus Remedies' R3SET forays into wellness
News | December 20, 2023

Venus Remedies' R3SET forays into wellness

The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey


Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Drug Approval | December 18, 2023

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation


Ami Organics inks agreement with Fermion for two additional APIs
News | December 18, 2023

Ami Organics inks agreement with Fermion for two additional APIs

The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25


Lupin receives USFDA approval for Allopurinol Tablets
Drug Approval | December 17, 2023

Lupin receives USFDA approval for Allopurinol Tablets

The product will be manufactured at Lupin's Pithampur facility in India


AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China
News | December 08, 2023

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II